N/A
Completed N=1,841
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
Source: ClinicalTrials.gov NCT01108796 ↗Enrolled (actual)
1,841
Serious AEs
0.1%
Results posted
Dec 2011
Primary outcomePrimary: Changes in Mean Blood Pressure (Systolic) After Treatment, Compared to Baseline — -30.71; -30.32; -30.35; -30.73 mmHg
Summary
This post-marketing surveillance study is designed to supplement the data on efficacy and tolerability of Micardis® and MicardisPlus® in patients at cardiovascular risk under general practice conditions.
The aim of the study is to investigate the effect of a six-month treatment with Micardis® / MicardisPlus® on blood pressure and the effect of the Lifestyle education tool for weight reduction on blood pressure control.
In addition, the post-marketing surveillance study will provide information on the effects on target measurement of the Lifestyle education tool and various laboratory parameters produced by treatment with Micardis® and MicardisPlus® in an unselected patient population under general practice conditions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Changes in Mean Blood Pressure (Systolic) After Treatment, Compared to Baseline |
-30.71; -30.32; -30.35; -30.73 | — |
| PRIMARY Changes in Mean Blood Pressure (Diastolic) After Treatment, Compared to Baseline |
-14.73; -15.31; -15.29; -14.65 | — |
| SECONDARY Changes in Laboratory Parameters:Low Density Lipoprotein (LDL) |
-0.41; -0.51; -0.50; -0.40 | — |
| SECONDARY Changes in Laboratory Parameters:High Density Lipoprotein (HDL) |
0.11; 0.09; 0.12; 0.06 | — |
| SECONDARY Changes in Laboratory Parameters: Triglycerides |
-0.24; -0.30; -0.32; -0.18 | — |
| SECONDARY Changes in Laboratory Parameters: Blood Glucose |
-0.49; -0.45; -0.49; -0.42 | — |
| SECONDARY Assessment of Metabolic Effect |
544; 695; 835; 404; 222; 361 | — |
Eligibility Criteria
Inclusion criteria
- Patients with essential hypertension (blood pressure (BP) higher or equal to 140/90 mmHg or higher or equal to 130/80 mmHg in case of diabetic patients)
- Patients with hypertension under treatment with one or more antihypertensive drug
Exclusion criteria
Patients are excluded according to the summary of product characteristics (SmPC).
Data sourced from ClinicalTrials.gov (NCT01108796). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.